Publications by authors named "Matthew A Wikler"

Claim this Profile
P
Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.
G Ralph Corey, Francis F Arhin, Matthew A Wikler, Daniel F Sahm, Barry N Kreiswirth

Int J Antimicrob Agents· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting.
Daniel H Deck, Jennifer M Jordan, Thomas L Holland, Weihong Fan, Matthew A Wikler

Infect Dis Ther· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting.
Daniel H Deck, Jennifer M Jordan, Thomas L Holland, Weihong Fan, Matthew A Wikler

Infect Dis Ther· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains.
Ronald N Jones, Douglas J Biedenbach, Paul G Ambrose, Matthew A Wikler

Diagn Microbiol Infect Dis· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction of a reference to clinical laboratory standards institute interpretive criteria.
Matthew A Wikler, Mary Jane Ferraro

Clin Infect Dis· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem.
Sujata M Bhavnani, Jeffrey P Hammel, Brenda B Cirincione, Matthew A Wikler, Paul G Ambrose

Antimicrob Agents Chemother· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis.
Yunhua Chen, Elizabeth Garber, Qiuqu Zhao, Yigong Ge, Matthew A Wikler

Antimicrob Agents Chemother· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro antimicrobial activity of doripenem, a new carbapenem.
Yigong Ge, Matthew A Wikler, Daniel F Sahm, Renée S Blosser-Middleton, James A Karlowsky

Antimicrob Agents Chemother· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin.
Lawrence D Sher, Michael D Poole, Kristen Von Seggern, Matthew A Wikler, Susan C Nicholson

Otolaryngol Head Neck Surg· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study.
Mark Gotfried, Thomas C Quinn, Samantha Gothelf, Matthew A Wikler, C Douglas Webb

Diagn Microbiol Infect Dis· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and tolerability of gatifloxacin in community treatment of acute exacerbations of chronic bronchitis.
Antonio Anzueto, Mark Gotfried, Matthew A Wikler, Rene Russo, Susan C Nicholson

Clin Ther· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis